Last reviewed · How we verify
Anja Bisgaard Pinborg — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| No Lutinus + transfer day 6 | No Lutinus + transfer day 6 | marketed | monoamine oxidase inhibitor | monoamine oxidase A and B | Psychiatry | |
| Lutinus + transfer day 6 | Lutinus + transfer day 6 | marketed | Progesterone supplement | Progesterone receptor | Reproductive Medicine / Fertility | |
| No Lutinus + transfer day 7 | No Lutinus + transfer day 7 | marketed | Lipid-lowering agent | Cardiovascular | ||
| Lutinus + transfer day 7 | Lutinus + transfer day 7 | marketed | Progesterone supplement | Progesterone receptor | Reproductive Medicine / Fertility |
Therapeutic area mix
- Reproductive Medicine / Fertility · 2
- Cardiovascular · 1
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Breath of Life International Pharma Ltd · 1 shared drug class
- OmegaD LLC · 1 shared drug class
- Sanofi · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Anja Bisgaard Pinborg:
- Anja Bisgaard Pinborg pipeline updates — RSS
- Anja Bisgaard Pinborg pipeline updates — Atom
- Anja Bisgaard Pinborg pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Anja Bisgaard Pinborg — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/anja-bisgaard-pinborg. Accessed 2026-05-15.